KIMYRSA is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms
KIMYRSA is supplied as a sterile white to off-white or pink lyophilized powder in single-dose clear glass vials containing 1,200 mg of oritavancin
Manufacturer # 70842022501
Brand KIMYRSA™
Manufacturer Melinta Therapeutics Inc
Country of Origin United States
Application Antibiotic
Container Type Single-Dose Vial
Dosage Form Injection
Generic Drug Name Oritavancin
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 70842022501
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Strength 1,200 mg
Supplier_ID 3885243
Type Intravenous
UNSPSC Code 51282706
